Grifols/$GRFS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Ticker
$GRFS
Sector
Primary listing
Employees
23,800
Headquarters
Website
Grifols Metrics
BasicAdvanced
$7.6B
13.96
$0.64
1.19
$0.14
1.60%
Price and volume
Market cap
$7.6B
Beta
1.19
52-week high
$11.14
52-week low
$6.19
Average daily volume
736K
Dividend rate
$0.14
Financial strength
Current ratio
2.482
Quick ratio
0.892
Long term debt to equity
12.798
Total debt to equity
14.269
Dividend payout ratio (TTM)
27.73%
Interest coverage (TTM)
2.58%
Profitability
EBITDA (TTM)
2,044.166
Gross margin (TTM)
39.84%
Net profit margin (TTM)
4.96%
Operating margin (TTM)
19.57%
Effective tax rate (TTM)
35.89%
Revenue per employee (TTM)
$372,940
Management effectiveness
Return on assets (TTM)
4.58%
Return on equity (TTM)
5.89%
Valuation
Price to earnings (TTM)
13.963
Price to revenue (TTM)
0.691
Price to book
1.26
Price to tangible book (TTM)
-1.22
Price to free cash flow (TTM)
7.433
Free cash flow yield (TTM)
13.45%
Free cash flow per share (TTM)
1.197
Dividend yield (TTM)
1.60%
Growth
Revenue change (TTM)
7.31%
3-year revenue growth (CAGR)
10.65%
10-year revenue growth (CAGR)
7.09%
10-year earnings per share growth (CAGR)
-3.50%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Grifols News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $7.6B as of December 06, 2025.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 13.96 as of December 06, 2025.
Does Grifols stock pay dividends?
Yes, the Grifols (GRFS) stock pays dividends to shareholders. As of December 06, 2025, the dividend rate is $0.14238 and the yield is 1.6%. Grifols has a payout ratio of 27.73% on a trailing twelve-month basis.
When is the next Grifols dividend payment date?
The next Grifols (GRFS) dividend payment date is unconfirmed.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.